207 related articles for article (PubMed ID: 29569795)
21. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
[TBL] [Abstract][Full Text] [Related]
23. Activation of sterol regulatory element-binding protein 1 (SREBP1)-mediated lipogenesis by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) promotes cell proliferation and progression of nasopharyngeal carcinoma.
Lo AK; Lung RW; Dawson CW; Young LS; Ko CW; Yeung WW; Kang W; To KF; Lo KW
J Pathol; 2018 Oct; 246(2):180-190. PubMed ID: 29968360
[TBL] [Abstract][Full Text] [Related]
24. Establishment and Characterization of an Epstein-Barr Virus-positive Cell Line from a Non-keratinizing Differentiated Primary Nasopharyngeal Carcinoma.
Chai AWY; Yee SM; Lee HM; Abdul Aziz N; Yee PS; Marzuki M; Wong KW; Chiang AKS; Chow LK; Dai W; Liu TF; Tan LP; Khoo ASB; Lo KW; Lim PVH; Rajadurai P; Lightfoot H; Barthorpe S; Garnett MJ; Cheong SC
Cancer Res Commun; 2024 Mar; 4(3):645-659. PubMed ID: 38358347
[TBL] [Abstract][Full Text] [Related]
25. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells.
Murono S; Inoue H; Tanabe T; Joab I; Yoshizaki T; Furukawa M; Pagano JS
Proc Natl Acad Sci U S A; 2001 Jun; 98(12):6905-10. PubMed ID: 11381123
[TBL] [Abstract][Full Text] [Related]
26. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma.
Yoshizaki T; Horikawa T; Qing-Chun R; Wakisaka N; Takeshita H; Sheen TS; Lee SY; Sato H; Furukawa M
Clin Cancer Res; 2001 Jul; 7(7):1946-51. PubMed ID: 11448908
[TBL] [Abstract][Full Text] [Related]
27. Latent membrane protein 1 mediates the resistance of nasopharyngeal carcinoma cells to TRAIL-induced apoptosis by activation of the PI3K/Akt signaling pathway.
Li SS; Yang S; Wang S; Yang XM; Tang QL; Wang SH
Oncol Rep; 2011 Dec; 26(6):1573-9. PubMed ID: 21850380
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
[TBL] [Abstract][Full Text] [Related]
29. Translational genomics of nasopharyngeal cancer.
Tsang CM; Lui VWY; Bruce JP; Pugh TJ; Lo KW
Semin Cancer Biol; 2020 Apr; 61():84-100. PubMed ID: 31521748
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus encoded microRNA BART7 regulates radiation sensitivity of nasopharyngeal carcinoma.
Gao W; Li ZH; Chen S; Chan JY; Yin M; Zhang MJ; Wong TS
Oncotarget; 2017 Mar; 8(12):20297-20308. PubMed ID: 28423621
[TBL] [Abstract][Full Text] [Related]
31. Combination of pigment epithelium-derived factor with radiotherapy enhances the antitumor effects on nasopharyngeal carcinoma by downregulating vascular endothelial growth factor expression and angiogenesis.
Xu Z; Fang S; Zuo Y; Zhang Y; Cheng R; Wang Q; Yang Z; Cai W; Ma J; Yang X; Gao G
Cancer Sci; 2011 Oct; 102(10):1789-98. PubMed ID: 21707863
[TBL] [Abstract][Full Text] [Related]
32. Differences in cancer gene copy number alterations between Epstein-Barr virus-positive and Epstein-Barr virus-negative nasopharyngeal carcinoma.
Ooft ML; van Ipenburg J; van de Loo RJM; de Jong R; Moelans CB; de Bree R; de Herdt MJ; Koljenović S; Baatenburg de Jong R; Hardillo J; Willems SM
Head Neck; 2018 Sep; 40(9):1986-1998. PubMed ID: 29927011
[TBL] [Abstract][Full Text] [Related]
33. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
34. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells.
Klibi J; Niki T; Riedel A; Pioche-Durieu C; Souquere S; Rubinstein E; Le Moulec S; Guigay J; Hirashima M; Guemira F; Adhikary D; Mautner J; Busson P
Blood; 2009 Feb; 113(9):1957-66. PubMed ID: 19005181
[TBL] [Abstract][Full Text] [Related]
35. Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells.
Lo AK; Dawson CW; Young LS; Ko CW; Hau PM; Lo KW
J Pathol; 2015 Oct; 237(2):238-48. PubMed ID: 26096068
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma.
Fogg M; Murphy JR; Lorch J; Posner M; Wang F
Virology; 2013 Jul; 441(2):107-13. PubMed ID: 23601786
[TBL] [Abstract][Full Text] [Related]
37. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.
Tu C; Zeng Z; Qi P; Li X; Yu Z; Guo C; Xiong F; Xiang B; Zhou M; Gong Z; Liao Q; Yu J; He Y; Zhang W; Li X; Li Y; Li G; Xiong W
J Virol; 2017 Sep; 91(17):. PubMed ID: 28637758
[TBL] [Abstract][Full Text] [Related]
38. Targeting exosomes enveloped EBV-miR-BART1-5p-antagomiRs for NPC therapy through both anti-vasculogenic mimicry and anti-angiogenesis.
Wang J; Liu Y; Zhang Y; Li X; Fang M; Qian D
Cancer Med; 2023 Jun; 12(11):12608-12621. PubMed ID: 37097161
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
